| Delenex Therapeutics AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20110159008 | Antibodies Binding To The Extracellular Domain Of The Receptor Tyrosine Kinase ALK - The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma. | 06-30-2011 |
| 20110020220 | HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE - The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed. | 01-27-2011 |
| 20110002927 | ANTIGEN-BINDING POLYPEPTIDES AGAINST CARTILAGE DEGENERATION - The invention provides an antigen-binding polypeptide which is able to penetrate into the cartilage. The disclosed polypeptide, compositions and methods are suitable for the treatment, prevention and/or delay of progression of cartilage degeneration. | 01-06-2011 |
